Q1 FY27 results analysis · July 24, 2026

Dr Lal Pathlabs Ltd (LALPATHLAB) Q1 FY27 Results Analysis: PAT Jumps 28%, Acquisition Spree Continues

+28.0%PAT year on year, Rs. 169.50 Cr
Cofacto ResearchPublished July 24, 20262 min readPositive read
Quick summary

Dr Lal Pathlabs Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 797.70 Cr (+19.10% YoY) and PAT growth of +28.02% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 24, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 797.70 Cr (+19.10% YoY)
PAT (Q1)Rs. 169.50 Cr (+28.02% YoY)
EBITDA margin31.03% (+232 bps YoY)
EPS (Q1)Rs. 10.15 (+27.83% YoY)
Market capRs. 29,497.83 Cr
CMPRs. 1,759.20

Quarter Snapshot

Q1 revenue grew 19.1% YoY to Rs.797.7 Cr, with EBITDA margin expanding 232 bps to 31.0%. PAT attributable to owners rose 28% YoY. The company completed one acquisition and proposed another, expanding its network, though the sustainability of the elevated margin remains to be seen.

Key Investment Insights

Key Positives

  • Revenue grew 19.1% YoY to Rs.797.7 Cr, accelerating from FY26 run-rate of ~12%.
  • EBITDA margin expanded 232 bps YoY to 31.03%.
  • PAT attributable to owners grew 28.02% YoY to Rs.169.5 Cr.
  • Employee benefits ratio compressed 192 bps YoY to 16.64% of revenue.
  • Acquisition of Shahbazkers Diagnostic Centre completed, expanding network.
  • Proposed acquisition of 80% stake in Sunshine Healthcare (Ghana) for up to Rs.380 Mn.

Risk Factors

  • Channel-partner fee ratio edged up to 14.52% from 14.30% YoY, a potential margin drag if growth slows.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.